Skip to content
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate

Our Pipeline

  • Portfolio
  • Compounds
  • Regimens
  • Partners
  • Trials

TB must be treated with multiple drugs to achieve maximal efficacy and prevent resistance. To transform treatment, novel TB regimens are needed. TB Alliance aims to register new drugs in combination with one another, or with existing TB drugs. The following regimens have been or currently are the subject of TB Alliance clinical trials.

BCZ

BCZPa

BPaL

BPaMZ

BPaZ

PaMZ

Pediatric HRZE

TBAJ-876 + pretomanid + linezolid

  • About
  • Why New TB Drugs
  • R&D
  • Access
  • News
New York: 80 Pine Street, 20th floor, New York, NY 10005 • +1 212 227 7540

Johannesburg: Spaces Atrium on 5th, 9th Floor, 5th Street, Sandton, Johannesburg, 2196, South Africa • +27 12 991 6328
Press Inquiries

Jess Wiggs
p | +1 646 616 8613
e | jessica.wiggs@tballiance.org
Jobs

View job openings
Join our mailing list

© 2025 The TB Alliance. All Rights Reserved. Report a Concern | Privacy Policy

In the first fifteen years following BPaL’s approval, more than 2 million people treated for drug-resistant TB will be treated with BPaL/M. This means millions of people will benefit from improved treatment outcomes and experiences.

BPaL/M has higher treatment success rates than previous therapies and use of these regimens is rapidly scaling up globally. In its first 15 years of approval, BPaL will save an additional 190,000 lives by replacing older treatments with lower success rates.

When TB doesn’t kill, it often leaves people with long periods of disability. By curing drug-resistant TB faster and more effectively, BPaL/M helps people not only survive, but recover faster, and avoid long term disabilities.  That means fewer years lost to illness and more people living fully again, faster. In its first 15 years of approval, BPaL will result in people experiencing more than 5,000,000 more healthy years of life.

332,654 Additional Treatment Successes

People who do not complete treatment and/or follow-up are not considered to have successful treatment outcomes. Thus, additional treatment successes are about more than just “lives saved.” In its first 15 years of approval, BPaL/M will lead to more than 330,000 additional people with drug-resistant TB being successfully treated.

179,697 more people will complete treatment

Traditionally, many people receiving treatment for drug-resistant TB did not complete therapy. This was often due to the length and side effects of treatments. Those who don’t complete treatment may remain contagious and infect others, as well as suffer increased disability or death. In its first 15 years of approval, BPaL/M will lead to nearly 180,000 additional people completing treatment.

BPaL/M drastically reduces the cost of fighting drug-resistant TB for individuals, families, and governments. Hospital visits are fewer, and medicines are more affordable. As a result, in the first 15 years of approval, BPaL/M will save health systems nearly $1.3B globally. Shorter treatments also mean reduced out of pocket costs and time out of work for people getting treated.

BPaL/M drastically reduces the cost of fighting drug-resistant TB for individuals, families, and governments. Hospital visits are fewer, and medicines are more affordable. As a result, in the first 15 years of approval, BPaL/M will save health systems nearly $1.3B globally. Shorter treatments also mean reduced out of pocket costs and time out of work for people getting treated.

The BPaL/M treatment costs less than $2 per day, however the vast majority of cost savings from implementing these new regimens is achieved through shorter and simpler treatment, reducing human and financial burden on health systems. This allows for the expansion of DR-TB care where costs and human resources have previously limited health systems’ capacities to treat DR-TB.